Evidence map›Paper›PMID 41755879›Full record

ArticleJACS Au2026

Highly Potent Th1-Type NKT Cell Agonists as Immunotherapeutic Agents via Conformational Restriction Design.

Yu Wen, Ye-Hui Wu, Qian-Nan Sun, En-Yang Wang, Meng-Qiang Luo, Zi-Run Fu, Zheng Zhou, De-Xiang Mei, Jun Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu WenInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Ye-Hui WuInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Qian-Nan SunInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
En-Yang WangInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Meng-Qiang LuoInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Zi-Run FuInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Zheng ZhouInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
De-Xiang MeiInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Jun GuoInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.ORCID https://orcid.org/0000-0002-2097-5054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Th1-selective natural killer T (NKT) cell agonists are promising immunotherapeutic agents due to their ability to promote cellular immunity against tumors and intracellular pathogens. However, the development of potent Th1-biased NKT cell agonists has remained slow despite decades of structural modification of the prototypical Th0-type agonist α-galactosylceramide (αGalCer). In this work, we used a distinct conformational restriction strategy to design a series of αGalCer branched analogs based on the spatial architecture of the CD1d binding groove, rather than through residue-focused modifications in previous αGalCer derivatizations. The linear acyl chain of αGalCer was replaced with branched motifs to restrict flexibility and enhance binding stability. Two optimized candidates

Indexed as

branched chainconformational restrictionglycolipidimmunotherapyNKT cell agonistα-galactosylceramide

Identifiers

PMID41755879
PMCPMC12933369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.